• Psyched Wellness has initiated a clinical study of its AME-1 as a sleep-enhancing food supplement
  • Psyched Wellness aims to develop new treatments that minimize residual hangover effects and increase alertness during the day
  • Positive results from this clinical study will allow the company to write a claim on the future AME-1 supplement that the product can help with sleep
  • Psyched Wellness Ltd. is a Canadian-based health supplements company dedicated to the distribution of mushroom-derived products
  • Psyched Wellness Ltd. (PSYC) opened trading at C$0.165 per share

Psyched Wellness (PSYC) has initiated a clinical study of its AME-1 as a sleep-enhancing food supplement for self-declared insomniacs.

Conventional and over-the-counter sleep medications can cause residual drowsiness. Psyched Wellness aims to develop new treatments that minimize residual hangover effects and increase alertness during the day.

Professor David Nutt, Board member and head of the company’s scientific committee, said,

“Psyched Wellness is researching the hugely important field of sleep and its disorders, and the company’s proprietary AME-1 has the potential to assist with these. Positive results from this clinical study will allow the company to write a claim on the future AME-1 supplement that the product can help with sleep while also improving daytime functioning.”

“Completing the sleep study and obtaining a structure/function claim for AME-1 is a very significant milestone, not only for the company but for everyone that suffers from insomnia and sleeping disorders,” said David Shisel, COO of Psyched Wellness.

“Developing a natural Amanita Muscaria Mushroom food supplement that has been clinically proven in human trials to help with sleeping disorders is very promising to the company and to consumers world-wide.”

Psyched Wellness is a Canadian-based health supplements company dedicated to the distribution of mushroom-derived products and associated consumer packaged goods. The company is in the process of developing a line of Amanita muscaria-derived water-based extracts, teas and capsules designed to promote stress relief and assist with restful sleeping.

Psyched Wellness Ltd. (PSYC) opened trading at C$0.165 per share.

More From The Market Online

Psychedelic stock begins take-home LSD microdosing clinical trial

MindBio Therapeutics (CSE:MBIO) secures approvals for MB22001 – a form of LSD – microdosing use by patients in a controlled clinical trial.

Red Light Holland begins experimental research on psilocybin truffles

Red Light Holland has revealed that it has officially begun an experimental research project on its psilocybin truffles.
MindBio Therapeutics chief executive officer Justin Hanka.

Psychedelic stock clears hurdle to treating depression with LSD

Psychedelic stock MindBio (CSE:MBIO) is revealing positive top-line data from its pioneering microdosing clinical trial to treat depression.

Clearmind Medicine to begin alcohol use disorder clinical trial

Clearmind Medicine (CSE:CMND) has received approval to begin its phase I/IIa clinical trial for alcohol use disorder in Israel.